{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:44:50Z","timestamp":1791315890865,"version":"4.3.1"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T00:00:00Z","timestamp":1613520000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T00:00:00Z","timestamp":1613520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"the Natural Science Foundation of Fujian Province","award":["2018Y0037"],"award-info":[{"award-number":["2018Y0037"]}]},{"DOI":"10.13039\/501100017686","name":"Fujian Provincial Health Technology Project","doi-asserted-by":"crossref","award":["2019-CX-19"],"award-info":[{"award-number":["2019-CX-19"]}],"id":[{"id":"10.13039\/501100017686","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s00415-021-10448-2","type":"journal-article","created":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T07:08:45Z","timestamp":1613718525000},"page":"664-675","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Risk of intracranial hemorrhage with direct oral anticoagulants: a systematic review and meta-analysis of randomized controlled\u00a0trials"],"prefix":"10.1007","volume":"269","author":[{"given":"Tingting","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyang","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lishui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meina","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaojun","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5629-0348","authenticated-orcid":false,"given":"Jinhua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,17]]},"reference":[{"key":"10448_CR1","doi-asserted-by":"publisher","first-page":"967","DOI":"10.2147\/TCRM.S84210","volume":"11","author":"YH Mekaj","year":"2015","unstructured":"Mekaj YH, Mekaj AY, Duci SB, Miftari EI (2015) New oral anticoagulants: Their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Ther Clin Risk Manag 11:967\u2013977","journal-title":"Ther Clin Risk Manag"},{"issue":"28","key":"10448_CR2","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1093\/eurheartj\/ehu181","volume":"35","author":"GY Lip","year":"2014","unstructured":"Lip GY, Agnelli G (2014) Edoxaban: A focused review of its clinical pharmacology. Eur Heart J 35(28):1844\u20131855","journal-title":"Eur Heart J"},{"issue":"3","key":"10448_CR3","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.cll.2014.06.003","volume":"34","author":"JH Levy","year":"2014","unstructured":"Levy JH (2014) Pharmacology and safety of new oral anticoagulants: the challenge of bleeding persists. Clin Lab Med 34(3):443\u2013452","journal-title":"Clin Lab Med"},{"issue":"9","key":"10448_CR4","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1007\/s00228-013-1510-z","volume":"69","author":"S Harder","year":"2013","unstructured":"Harder S, Graff J (2013) Novel oral anticoagulants: clinical pharmacology, indications and practical considerations. Eur J Clin Pharmacol 69(9):1617\u20131633","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"10448_CR5","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1159\/000177034","volume":"32","author":"HC Kim","year":"2009","unstructured":"Kim HC, Choi DP, Ahn SV, Nam CM, Suh I (2009) Six-year survival and causes of death among stroke patients in Korea. Neuroepidemiology 32(2):94\u2013100","journal-title":"Neuroepidemiology"},{"issue":"8","key":"10448_CR6","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.amjmed.2006.07.034","volume":"120","author":"MC Fang","year":"2007","unstructured":"Fang MC, Go AS, Chang Y et al (2007) Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med 120(8):700\u2013705","journal-title":"Am J Med"},{"issue":"6","key":"10448_CR7","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1161\/STROKEAHA.112.650614","volume":"43","author":"RG Hart","year":"2012","unstructured":"Hart RG, Diener HC, Yang S et al (2012) Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke 43(6):1511\u20131517","journal-title":"Stroke"},{"issue":"3","key":"10448_CR8","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1007\/s00415-014-7462-0","volume":"262","author":"D Caldeira","year":"2014","unstructured":"Caldeira D, Barra M, Pinto FJ, Ferreira JJ, Costa J (2014) Intracranial hemorrhage risk with the new oral anticoagulants: A systematic review and meta-analysis. J Neurol 262(3):516\u2013522","journal-title":"J Neurol"},{"issue":"7","key":"10448_CR9","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1111\/jth.14131","volume":"16","author":"Z Wolfe","year":"2018","unstructured":"Wolfe Z, Khan SU, Nasir F, Subramanian CR, Lash B (2018) A systematic review and bayesian network meta-analysis of risk of intracranial hemorrhage with direct oral anticoagulants. J Thromb Haemost 16(7):1296\u20131306","journal-title":"J Thromb Haemost"},{"key":"10448_CR10","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, Group P; PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535","journal-title":"BMJ"},{"key":"10448_CR11","unstructured":"Higgins JPT (2011) Cochrane handbook for systematic reviews of interventions Version 5.1.0. Chichester, England: The Cochrane Collaboration"},{"issue":"17","key":"10448_CR12","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","volume":"382","author":"G Agnelli","year":"2020","unstructured":"Agnelli G, Becattini C, Meyer G et al (2020) Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 382(17):1599\u20131607","journal-title":"N Engl J Med"},{"issue":"9","key":"10448_CR13","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1302507","volume":"369","author":"G Agnelli","year":"2013","unstructured":"Agnelli G, Buller HR, Cohen A et al (2013) Oral Apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369(9):799\u2013808","journal-title":"N Engl J Med"},{"issue":"4","key":"10448_CR14","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1161\/STROKEAHA.119.027569","volume":"51","author":"KS Butcher","year":"2020","unstructured":"Butcher KS, Ng K, Sheridan P et al (2020) Dabigatran treatment of acute noncardioembolic ischemic stroke. Stroke 51(4):1190\u20131198","journal-title":"Stroke"},{"issue":"14","key":"10448_CR15","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","volume":"366","author":"HR B\u00fcller","year":"2012","unstructured":"B\u00fcller HR, Prins MH, Lensin AW et al (2012) Oral Rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366(14):1287\u20131297","journal-title":"N Engl J Med"},{"issue":"15","key":"10448_CR16","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","volume":"369","author":"HR B\u00fcller","year":"2013","unstructured":"B\u00fcller HR, D\u00e9cousus H, Grosso MA et al (2013) Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 369(15):1406\u20131415","journal-title":"N Engl J Med"},{"issue":"17","key":"10448_CR17","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1701005","volume":"376","author":"H Calkins","year":"2017","unstructured":"Calkins H, Willems S, Gerstenfeld EP et al (2017) Uninterrupted dabigatran versus warfarin for ablation in atrial fibrillation. N Engl J Med 376(17):1627\u20131636","journal-title":"N Engl J Med"},{"issue":"47","key":"10448_CR18","doi-asserted-by":"publisher","first-page":"3346","DOI":"10.1093\/eurheartj\/ehu367","volume":"35","author":"R Cappato","year":"2014","unstructured":"Cappato R, Ezekowitz MD, Klein AL et al (2014) Rivaroxaban vs vitamin K antagonists forcardioversion in atrial fibrillation. Eur Heart J 35(47):3346\u20133355","journal-title":"Eur Heart J"},{"issue":"6","key":"10448_CR19","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1177\/1074248420929483","volume":"25","author":"TW Chapin","year":"2020","unstructured":"Chapin TW, Leedahl DD, Brown AB et al (2020) Comparison of anticoagulants for postoperative atrial fibrillationafter coronary artery bypass grafting: A Pilot Study. J Cardiovasc Pharmacol Ther 25(6):523\u2013530","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"3","key":"10448_CR20","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1160\/TH10-07-0451","volume":"105","author":"N Chung","year":"2011","unstructured":"Chung N, Jeon HK, Lien LM et al (2011) Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non-valvular atrial fibrillation. Thromb Haemost 105(3):535\u2013544","journal-title":"Thromb Haemost"},{"issue":"6","key":"10448_CR21","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1056\/NEJMoa1111096","volume":"368","author":"AT Cohen","year":"2013","unstructured":"Cohen AT, Spiro TE, B\u00fcller HR et al (2013) Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med 368(6):513\u2013523","journal-title":"N Engl J Med"},{"issue":"12","key":"10448_CR22","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361(12):1139\u20131151","journal-title":"N Engl J Med"},{"issue":"9","key":"10448_CR23","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1056\/NEJMoa1007432","volume":"364","author":"SJ Connolly","year":"2011","unstructured":"Connolly SJ, Eikelboom J, Joyner C et al (2011) Apixaban in patients with atrial fibrillation. N Engl J Med 364(9):806\u2013817","journal-title":"N Engl J Med"},{"issue":"1","key":"10448_CR24","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1681\/ASN.2019060579","volume":"31","author":"AS De Vriese","year":"2020","unstructured":"De Vriese AS, Caluw\u00e9 R, Pyfferoen L et al (2020) Multicenter randomized controlled trial of vitamin K antagonist replacement by rivaroxaban with or without vitamin K2 in hemodialysispatients with atrial fibrillation: the Valkyrie Study. J Am Soc Nephrol 31(1):186\u2013196","journal-title":"J Am Soc Nephrol"},{"issue":"20","key":"10448_CR25","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1056\/NEJMoa1813959","volume":"380","author":"HC Diener","year":"2019","unstructured":"Diener HC, Sacco RL, Easton JD et al (2019) Dabigatran for prevention of stroke after embolic stroke of undetermined source. N Engl J Med 380(20):1906\u20131917","journal-title":"N Engl J Med"},{"key":"10448_CR26","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13018-015-0223-7","volume":"10","author":"W Du","year":"2015","unstructured":"Du W, Zhao CH, Wang JJ, Liu JQ, Shen BH, Zheng YP (2015) Comparison of rivaroxaban and parnaparin for preventing venous thromboembolism after lumbar spine surgery. J Orthop Surg Res 10:78","journal-title":"J Orthop Surg Res"},{"issue":"14","key":"10448_CR27","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","volume":"377","author":"JW Eikelboom","year":"2017","unstructured":"Eikelboom JW, Connolly SJ, Bosch J et al (2017) Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 377(14):1319\u20131330","journal-title":"N Engl J Med"},{"issue":"26","key":"10448_CR28","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","volume":"363","author":"R Bauersachs","year":"2010","unstructured":"Bauersachs R, Berkowitz SD, Brenner B et al (2010) Oral Rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363(26):2499\u20132510","journal-title":"N Engl J Med"},{"issue":"9591","key":"10448_CR29","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/S0140-6736(07)61445-7","volume":"370","author":"BI Eriksson","year":"2007","unstructured":"Eriksson BI, Dahl OE, Rosencher N et al (2007) Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 370(9591):949\u2013956","journal-title":"Lancet"},{"issue":"11","key":"10448_CR30","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1111\/j.1538-7836.2007.02748.x","volume":"5","author":"BI Eriksson","year":"2007","unstructured":"Eriksson BI, Dahl OE, Rosencher N et al (2007) Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 5(11):2178\u20132185","journal-title":"J Thromb Haemost"},{"issue":"26","key":"10448_CR31","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1056\/NEJMoa0800374","volume":"358","author":"BI Eriksson","year":"2008","unstructured":"Eriksson BI, Borris LC, Friedman RJ et al (2008) Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 358(26):2765\u20132775","journal-title":"N Engl J Med"},{"issue":"9","key":"10448_CR32","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1016\/j.amjcard.2007.06.034","volume":"100","author":"MD Ezekowitz","year":"2007","unstructured":"Ezekowitz MD, Reilly PA, Nehmiz G et al (2007) Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol 100(9):1419\u20131426","journal-title":"Am J Cardiol"},{"issue":"32","key":"10448_CR33","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1093\/eurheartj\/ehy148","volume":"39","author":"MD Ezekowitz","year":"2018","unstructured":"Ezekowitz MD, Pollack CV, Halperin JL et al (2018) Apixaban compared to heparin\/vitamin K antagonist in patients with atrial fibrillation scheduled forcardioversion: the EMANATE trial. Eur Heart J 39(32):2959\u20132971","journal-title":"Eur Heart J"},{"issue":"12","key":"10448_CR34","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1001\/jamaneurol.2019.2764","volume":"76","author":"JM Ferro","year":"2019","unstructured":"Ferro JM, Coutinho JM, Dentali F et al (2019) Safety and efficacy of dabigatran etexilate vs. dose-adjusted warfarin in patients with cerebral venous thrombosis: a randomized clinical trial. JAMA Neurol 76(12):1457\u20131465","journal-title":"JAMA Neurol"},{"issue":"1","key":"10448_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.arth.2008.01.132","volume":"24","author":"JS Ginsberg","year":"2009","unstructured":"Ginsberg JS, Davidson BL, Comp PC et al (2009) Oral Thrombin inhibitor dabigatran etexilate vs. north american enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 24(1):1\u20139","journal-title":"J Arthroplasty"},{"issue":"22","key":"10448_CR36","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","volume":"369","author":"RP Giugliano","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E et al (2013) Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369(22):2093\u20132104","journal-title":"N Engl J Med"},{"issue":"10055","key":"10448_CR37","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1016\/S0140-6736(16)31474-X","volume":"388","author":"A Goette","year":"2016","unstructured":"Goette A, Merino JL, Ezekowitz MD et al (2016) Edoxaban versus enoxaparin\u2013warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. Lancet 388(10055):1995\u20132003","journal-title":"Lancet"},{"issue":"23","key":"10448_CR38","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1056\/NEJMoa1110899","volume":"365","author":"SZ Goldhaber","year":"2011","unstructured":"Goldhaber SZ, Leizorovicz A, Kakkar AK et al (2011) Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med 365(23):2167\u20132177","journal-title":"N Engl J Med"},{"issue":"11","key":"10448_CR39","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJ et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365(11):981\u2013992","journal-title":"N Engl J Med"},{"key":"10448_CR40","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.vph.2018.05.002","volume":"113","author":"AS Hanafy","year":"2019","unstructured":"Hanafy AS, Abd-Elsalam S, Dawoud MM (2019) Randomized controlled trial of rivaroxaban versus warfarin in the management of acute non-neoplastic portal vein thrombosis. Vascul Pharmacol 113:86\u201391","journal-title":"Vascul Pharmacol"},{"issue":"23","key":"10448_CR41","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1056\/NEJMoa1802686","volume":"378","author":"RG Hart","year":"2018","unstructured":"Hart RG, Sharma M, Mundl H et al (2018) Rivaroxaban for stroke prevention after embolic stroke of undetermined source. N Engl J Med 378(23):2191\u20132201","journal-title":"N Engl J Med"},{"issue":"9","key":"10448_CR42","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1253\/circj.CJ-12-0454","volume":"76","author":"M Hori","year":"2012","unstructured":"Hori M, Matsumoto M, Tanahashi N et al (2012) Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation \u2013 the J-ROCKET AF Study. Circ J 76(9):2104\u20132111","journal-title":"Circ J"},{"issue":"9632","key":"10448_CR43","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(08)60880-6","volume":"372","author":"AK Kakkar","year":"2008","unstructured":"Kakkar AK, Brenner B, Dahl OE et al (2008) Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 372(9632):31\u201339","journal-title":"Lancet"},{"issue":"1","key":"10448_CR44","first-page":"20356","volume":"9","author":"JM Kang","year":"2019","unstructured":"Kang JM, Park KH, Ahn S et al (2019) Rivaroxaban after thrombolysis in acute iliofemoral venous thrombosis: a randomized, open-labeled. Multicenter trial Sci Rep 9(1):20356","journal-title":"Multicenter trial Sci Rep"},{"issue":"5","key":"10448_CR45","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1111\/jce.12928","volume":"27","author":"T Kuwahara","year":"2016","unstructured":"Kuwahara T, Abe M, Yamaki M et al (2016) Apixaban versus warfarin for the prevention of periprocedural cerebral thromboembolism in atrial fibrillation ablation: multicenter prospective randomized study. J Cardiovasc Electrophysiol 27(5):549\u2013554","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"9717","key":"10448_CR46","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/S0140-6736(09)62125-5","volume":"375","author":"MR Lassen","year":"2010","unstructured":"Lassen MR, Raskob GE, Gallus A et al (2010) Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 375(9717):807\u2013815","journal-title":"Lancet"},{"issue":"26","key":"10448_CR47","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1056\/NEJMoa1006885","volume":"363","author":"MR Lassen","year":"2010","unstructured":"Lassen MR, Gallus A, Raskob GE et al (2010) Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 363(26):2487\u20132498","journal-title":"N Engl J Med"},{"issue":"6","key":"10448_CR48","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1056\/NEJMoa0810773","volume":"361","author":"MR Lassen","year":"2009","unstructured":"Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ (2009) Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 361(6):594\u2013604","journal-title":"N Engl J Med"},{"issue":"1","key":"10448_CR49","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1016\/S2352-3026(19)30219-4","volume":"7","author":"C Male","year":"2020","unstructured":"Male C, Lensing AWA, Palumbo JS et al (2020) Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. Lancet Haematol 7(1):e18\u2013e27","journal-title":"Lancet Haematol"},{"issue":"4","key":"10448_CR50","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1177\/1708538113490423","volume":"22","author":"LZ Mao","year":"2014","unstructured":"Mao LZ, Li CY, Li T, Yuan KX (2014) Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in Chinese patients with atrial fibrillation. Vascular 22(4):252\u2013258","journal-title":"Vascular"},{"issue":"2","key":"10448_CR51","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/jth.14662","volume":"18","author":"RD McBane II","year":"2020","unstructured":"McBane RD II, Wysokinski WF, Le-Rademacher JG et al (2020) Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial. J Thromb Haemost 18(2):411\u2013421","journal-title":"J Thromb Haemost"},{"issue":"4","key":"10448_CR52","doi-asserted-by":"publisher","first-page":"e191994","DOI":"10.1001\/jamanetworkopen.2019.1994","volume":"2","author":"A Nogami","year":"2019","unstructured":"Nogami A, Harada T, Sekiguchi Y et al (2019) Safety and efficacy of minimally interrupted dabigatran vs uninterrupted warfarin therapy in adults undergoing atrial fibrillation catheter ablation: a randomized clinical trial. JAMA Netw Open 2(4):e191994","journal-title":"JAMA Netw Open"},{"issue":"8","key":"10448_CR53","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1253\/circj.CJ-10-1183","volume":"75","author":"S Ogawa","year":"2011","unstructured":"Ogawa S, Shinohara Y, Kanmuri K et al (2011) Safety and efficacy of the oral direct factor Xa inhibitor apixaban in Japanese patients with non-valvular atrial fibrillation\u2013the ARISTOTLE-J study. Circ J 75(8):1852\u20131859","journal-title":"Circ J"},{"issue":"10","key":"10448_CR54","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365(10):883\u2013891","journal-title":"N Engl J Med"},{"issue":"1","key":"10448_CR55","first-page":"95","volume":"379","author":"GE Raskob","year":"2018","unstructured":"Raskob GE, Es NV, Verhamme P et al (2018) Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 379(1):95\u201396","journal-title":"N Engl J Med"},{"issue":"8","key":"10448_CR56","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJMoa1113697","volume":"368","author":"S Schulman","year":"2013","unstructured":"Schulman S, Kearon C, Kakkar AK et al (2013) Extended Use of Dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 368(8):709\u2013718","journal-title":"N Engl J Med"},{"issue":"7","key":"10448_CR57","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1161\/CIRCULATIONAHA.113.004450","volume":"129","author":"S Schulman","year":"2014","unstructured":"Schulman S, Kakkar AK, Goldhaber SZ et al (2014) Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 129(7):764\u2013772","journal-title":"Circulation"},{"issue":"24","key":"10448_CR58","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","volume":"361","author":"S Schulman","year":"2009","unstructured":"Schulman S, Kearon C, Kakkar AK et al (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361(24):2342\u20132352","journal-title":"N Engl J Med"},{"issue":"12","key":"10448_CR59","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1016\/j.arth.2014.05.029","volume":"29","author":"T Fuji","year":"2014","unstructured":"Fuji T, Wang CJ, Fujita S, Kawai Y, Kimura T, Tachibana S (2014) Safety and efficacy of edoxaban, an oral factor Xa inhibitor, for thromboprophylaxis after total hip arthroplasty in Japan and Taiwan. J Arthroplasty 29(12):2439\u20132446","journal-title":"J Arthroplasty"},{"issue":"6","key":"10448_CR60","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.thromres.2014.03.009","volume":"133","author":"T Fuji","year":"2014","unstructured":"Fuji T, Fujita S, Kawai Y et al (2014) Safety and efficacy of edoxaban in patients undergoing hip fracture surgery. Thromb Res 133(6):1016\u20131022","journal-title":"Thromb Res"},{"issue":"6","key":"10448_CR61","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1016\/j.thromres.2014.09.011","volume":"134","author":"T Fuji","year":"2014","unstructured":"Fuji T, Wang CJ, Fujita S et al (2014) Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: The STARS E-3 Trial. Thromb Res 134(6):1198\u20131204","journal-title":"Thromb Res"},{"key":"10448_CR62","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12959-015-0057-x","volume":"13","author":"T Fuji","year":"2015","unstructured":"Fuji T, Fujita S, Kawai Y et al (2015) Efficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty: STARS J-V. Thromb J 13:27","journal-title":"Thromb J"},{"issue":"9676","key":"10448_CR63","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1016\/S0140-6736(09)60734-0","volume":"373","author":"AG Turpie","year":"2009","unstructured":"Turpie AG, Lassen MR, Davidson BL et al (2009) Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 373(9676):1673\u20131680","journal-title":"Lancet"},{"issue":"13","key":"10448_CR64","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1056\/NEJMoa1700518","volume":"376","author":"JI Weitz","year":"2017","unstructured":"Weitz JI, Lensing AWA, Prins MH et al (2017) Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med 376(13):1211\u20131222","journal-title":"N Engl J Med"},{"issue":"8","key":"10448_CR65","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1253\/circj.CJ-11-1140","volume":"76","author":"T Yamashita","year":"2012","unstructured":"Yamashita T, Koretsune Y, Yasaka M et al (2012) Randomized, multicenter, warfarin-controlled phase II study of edoxaban in Japanese patients with non-valvular atrial fibrillation. Circ J 76(8):1840\u20131847","journal-title":"Circ J"},{"issue":"20","key":"10448_CR66","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","volume":"36","author":"AM Young","year":"2018","unstructured":"Young AM, Marshall A, Thirlwall J et al (2018) Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 36(20):2017\u20132023","journal-title":"J Clin Oncol"},{"issue":"12","key":"10448_CR67","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/S1474-4422(10)70274-X","volume":"9","author":"HC Diener","year":"2010","unstructured":"Diener HC, Connolly SJ, Ezekowitz MD et al (2010) Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol 9(12):1157\u20131163","journal-title":"Lancet Neurol"},{"issue":"6","key":"10448_CR68","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/S1474-4422(12)70092-3","volume":"11","author":"JD Easton","year":"2012","unstructured":"Easton JD, Lopes RD, Bahit MC et al (2012) Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. Lancet Neurol 11(6):503\u2013511","journal-title":"Lancet Neurol"},{"issue":"4","key":"10448_CR69","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/S1474-4422(12)70042-X","volume":"11","author":"GJ Hankey","year":"2012","unstructured":"Hankey GJ, Patel MR, Stevens SR et al (2012) Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol 11(4):315\u2013322","journal-title":"Lancet Neurol"},{"key":"10448_CR70","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1161\/STROKEAHA.116.013540","volume":"47","author":"NS Rost","year":"2016","unstructured":"Rost NS, Giugliano RP, Ruff CT et al (2016) Outcomes with edoxaban versus warfarin in patients with previous cerebrovascular events: findings from ENGAGE AF-TIMI 48 (effective anticoagulation with Factor Xa next generation in atrial fibrillation-thrombolysis in myocardial infarction 48). Stroke 47:2075\u20132082","journal-title":"Stroke"},{"key":"10448_CR71","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/1477-7525-8-49","volume":"8","author":"DA Cadilhac","year":"2010","unstructured":"Cadilhac DA, Dewey HM, Vos T, Carter R, Thrift AG (2010) The health loss from ischemic stroke and Intracerebral hemorrhage: evidence from the North East Melbourne Stroke Incidence Study (NEMESIS). Health Qual Life Outcomes 8:49","journal-title":"Health Qual Life Outcomes"},{"issue":"4","key":"10448_CR72","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1161\/STROKEAHA.109.573543","volume":"41","author":"HY Lee","year":"2010","unstructured":"Lee HY, Hwang JS, Jeng JS, Wang JD (2010) Quality-adjusted life expectancy (QALE) and loss of QALE for patients with ischemic stroke and intracerebral hemorrhage: a13-year follow-up. Stroke 41(4):739\u2013744","journal-title":"Stroke"},{"issue":"10","key":"10448_CR73","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1016\/j.jstrokecerebrovasdis.2014.06.031","volume":"23","author":"R Grysiewicz","year":"2014","unstructured":"Grysiewicz R, Gorelick PB (2014) Incidence, mortality, and risk factors for oral anticoagulant\u2013associated intracranial hemorrhage in patients with atrial fibrillation. J Stroke Cerebrovasc Dis 23(10):2479\u20132488","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10448_CR74","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.1182\/blood-2016-08-731638","volume":"129","author":"RD Lopes","year":"2017","unstructured":"Lopes RD, Guimaraes PO, Kolls BJ et al (2017) Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation therapy. Blood 129:2980\u20132987","journal-title":"Blood"},{"key":"10448_CR75","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1161\/STROKEAHA.112.650614","volume":"43","author":"RG Hart","year":"2012","unstructured":"Hart RG, Diener HC, Yang S et al (2012) Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke 43:1511\u20131517","journal-title":"Stroke"},{"key":"10448_CR76","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1161\/STROKEAHA.113.004506","volume":"45","author":"GJ Hankey","year":"2014","unstructured":"Hankey GJ, Stevens SR, Piccini JP et al (2014) Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation. Stroke 45:1304\u20131312","journal-title":"Stroke"},{"issue":"15","key":"10448_CR77","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1080\/14656566.2020.1789099","volume":"21","author":"JM Rivera-Caravaca","year":"2020","unstructured":"Rivera-Caravaca JM, Esteve-Pastor MA, Camelo-Castillo A et al (2020) Treatment strategies for patients with atrial fibrillation and anticoagulant-associated intracranial hemorrhage: an overview of the pharmacotherapy. Expert Opin Pharmacother 21(15):1867\u20131881","journal-title":"Expert Opin Pharmacother"},{"issue":"8","key":"10448_CR78","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/s00415-006-0201-4","volume":"253","author":"JM Ferro","year":"2006","unstructured":"Ferro JM (2006) Update on intracerebral haemorrhage. J Neurol 253(8):985\u2013999","journal-title":"J Neurol"},{"issue":"3","key":"10448_CR79","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1161\/CIRCULATIONAHA.114.013267","volume":"132","author":"M Sharma","year":"2015","unstructured":"Sharma M, Cornelius VR, Patel JP, Davies JG, Molokhia M (2015) Efficacy and harms of direct oral anticoagulants in the elderly for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism: systematic review and meta-analysis. Circulation 132(3):194\u2013204","journal-title":"Circulation"},{"issue":"4","key":"10448_CR80","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.amjcard.2014.11.039","volume":"115","author":"L Touma","year":"2015","unstructured":"Touma L, Filion KB, Atallah R, Eberg M, Eisenberg MJ (2015) A meta-analysis of randomized controlled trials of the risk of bleeding with apixaban versus vitamin K antagonists. Am J Cardiol 115(4):533\u2013541","journal-title":"Am J Cardiol"},{"issue":"1","key":"10448_CR81","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1055\/s-0035-1568875","volume":"42","author":"N Riva","year":"2016","unstructured":"Riva N, Dentali F, Permunian ET, Ageno W (2016) Major bleeding and case fatality rate with the direct oral anticoagulants in orthopedic surgery: a systematic review and meta-analysis. Semin Thromb Hemost 42(1):42\u201354","journal-title":"Semin Thromb Hemost"},{"issue":"12","key":"10448_CR82","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1001\/jamaneurol.2018.2215","volume":"75","author":"WY Huang","year":"2018","unstructured":"Huang WY, Singer DE, Wu YL et al (2018) Association of intracranial hemorrhage risk with non\u2013vitaminK antagonist oral anticoagulant use vs aspirin use: a systematic review and meta-analysis. JAMA Neurol 75(12):1511\u20131518","journal-title":"JAMA Neurol"},{"key":"10448_CR83","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1161\/01.STR.0000170642.39876.f2","volume":"36","author":"RG Hart","year":"2005","unstructured":"Hart RG, Tonarelli SB, Pearce LA (2005) Avoiding central nervous system bleeding during antithrombotic therapy:recent data and ideas. Stroke 36:1588\u20131593","journal-title":"Stroke"},{"issue":"6","key":"10448_CR84","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1177\/1747493017700663","volume":"12","author":"G Ntaios","year":"2017","unstructured":"Ntaios G, Papavasileiou V, Diener HC, Makaritsis K, Michel P (2017) Nonvitamin-K-antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and previous stroke or transient ischemic attack: An updated systematic review and meta-analysis of randomized controlled trials. Int J Stroke 12(6):589\u2013596","journal-title":"Int J Stroke"},{"issue":"4","key":"10448_CR85","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s10557-020-06961-7","volume":"34","author":"X Liu","year":"2020","unstructured":"Liu X, Xu ZX, Yu P, Yuan P, Zhu WG (2020) Non-vitamin K antagonist oral anticoagulants in secondary stroke prevention in atrial fibrillation patients: an updated analysis by adding observational studies. Cardiovasc Drugs Ther 34(4):569\u2013578","journal-title":"Cardiovasc Drugs Ther"},{"issue":"12","key":"10448_CR86","first-page":"1486","volume":"70","author":"S Chatterjee","year":"2013","unstructured":"Chatterjee S, Sardar P, Biondi-Zoccai G, Kumbhani DJ (2013) New oral Anticoagulants and the risk of intracranial hemorrhage: traditional and Bayesian meta-analysis and mixed treatment comparison of randomized trials of new oral anticoagulants in atrial fibrillation. JAMA Neurol 70(12):1486\u20131490","journal-title":"JAMA Neurol"},{"issue":"1","key":"10448_CR87","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3390\/jpm9010007","volume":"9","author":"SH Kanuri","year":"2019","unstructured":"Kanuri SH, Kreutz RP (2019) Pharmacogenomics of novel direct oral anticoagulants: newly identified genes and genetic variants. J Pers Med 9(1):7","journal-title":"J Pers Med"},{"key":"10448_CR88","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1093\/europace\/euv124","volume":"17","author":"H Heidbuchel","year":"2015","unstructured":"Heidbuchel H, Vrijens B (2015) Non-vitamin K antagonist oral anticoagulants (NOAC): considerations on once- vs. twice-daily regimens and their potential impact on medication adherence. EP Europace 17:1317\u20131318","journal-title":"EP Europace"},{"issue":"16","key":"10448_CR89","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","volume":"39","author":"J Steffel","year":"2018","unstructured":"Steffel J, Verhamme P, Potpara TS et al (2018) The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 39(16):1330\u20131393","journal-title":"Eur Heart J"},{"key":"10448_CR90","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/S0009-9236(98)90130-8","volume":"64","author":"JJ Lilja","year":"1998","unstructured":"Lilja JJ, Kivisto KT, Neuvonen PJ (1998) Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. Clin Pharmacol Ther 64:477\u2013483","journal-title":"Clin Pharmacol Ther"},{"key":"10448_CR91","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.clpt.2006.09.003","volume":"80","author":"PJ Neuvonen","year":"2006","unstructured":"Neuvonen PJ, Niemi M, Backman JT (2006) Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 80:565\u2013581","journal-title":"Clin Pharmacol Ther"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-021-10448-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-021-10448-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-021-10448-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T04:16:20Z","timestamp":1650255380000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-021-10448-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,17]]},"references-count":91,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["10448"],"URL":"https:\/\/doi.org\/10.1007\/s00415-021-10448-2","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,17]]},"assertion":[{"value":"10 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"No ethics approval or patient consent was obtained because all data used in this study were collected from previously published studies.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standard"}}]}}